An AI technology that makes the world's
medicines faster?

Hyper Lab Blog

Beyond new drug development, sharing pharmaceutical and biotech news.

Most Recent
The 30-Year-Old Secret Behind  AlphaFold's Success.png
AI
The 30-Year-Old Secret Behind AlphaFold's Success
Originally developed 30 years ago, the traditional MSA technique has dramatically enhanced AlphaFold’s protein structure prediction accuracy, bringing it back into the spotlight after years of relative obscurity.
Junhyeok Jeon, AI Researcher2024.12.16
Cobenfy_ A paradigm shift after 70 years, a new path in schizophrenia treatment.png
Drug Discovery
Cobenfy: Redefining Schizophrenia Treatment After 70 Years
Cobenfy is an FDA-approved oral schizophrenia treatment targeting muscarinic rather than dopamine receptors. Its rapid symptom improvement and fewer side effects hint at a paradigm shift, making upcoming clinical findings highly anticipated.
Seungmin Jung, R&D Starategy Team Researcher2024.12.10
2.png
AI
Protein Structure Based Drug Design - Docking Environment Setup
Did you know that molecular docking, a key tool in drug discovery, can yield vastly different results depending on how you configure settings like thoroughness, scoring functions, and flexible residues?
Sehan Lee, AI research 2 Team Lead2024.11.29
Innovation and Future of Ultra-large Compound Libraries.png
AI
Innovation and Future of Ultra-large Compound Libraries
Ultra-large compound libraries leverage DEL technology and AI to increase the efficiency of drug discovery, expanding chemical diversity and the potential for hit discovery.
Jaechang Lim, CTO2024.11.29
Reflections on the Excellence Award at the 2nd AI Drug Discovery Competition (1).png
AI
Reflections on the Excellence Award at the 2nd AI Drug Discovery Competition
Sunghan Bae from the HITS AI research team won the 2nd AI Drug Discovery Competition, utilizing the MolClr model and HyperLab's binding affinity predictions to overcome data shortages and imbalances.
Sunghan Bae, AI Researcher2024.11.22
FDA Grants Accelerated Approval for the First Primary Biliary Cholangitis (PBC) Treatment, Seladelpar (1).png
Drug Discovery
FDA Grants Accelerated Approval for the First Primary Biliary Cholangitis (PBC) Treatment, ‘Seladelpar’
Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.
Heejin Jung, R&D Strategy Team Lead2024.10.18
Novel drugs first shown at EFMC-ISMC 2024.png
Pharmaceutical
Novel drugs first shown at EFMC-ISMC 2024
We describe the clinical development status and characteristics of seven new drugs first presented at EFMC-ISMC in 2024.
Seungmin Jung, R&D Starategy Team Researcher2024.09.12
Hyper Lab Interview - Georgia Institute of technology (1).png
AI
Hyper Lab Interview with Georgia Institute of technology
We interviewed Ryan Kern from the Georgia Institute of technology about the Hyper Lab, and how it integrates experimentation and computation, and has proven to be very useful in optimizing drug candidates.
HITS Hyper Lab TEAM2024.09.02
제목 (1).png
Pharmaceutical
EFMC-ISMC 2024 Preview
EFMC-ISMC 2024 is an international pharmacology symposium taking place September 1-5 in Rome, Italy, and is divided into three main sessions. HITS will be introducing Hyper Lab, an AI drug discovery platform.
Seungmin Jung, R&D Starategy Team Researcher2024.08.19
제목.png
Pharmaceutical
Watching AI-discovered materials develop
It's been a decade since AI entered the drug discovery race, but where are we in the pipeline of drugs discovered by AI-powered drug discovery platforms? In this post, we'll summarize the targets and trends in their development.
Heejin Jung, R&D Strategy Team Lead2024.08.13